Sequencing Therapies: Optimal Treatment for HR+/HER2– Metastatic Breast Cancer

H&O  What are the options for first-line treatment of patients with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) metastatic breast cancer? VK  The […]

Expanding the Use of PARP Inhibitors in Breast Cancer

H&O  Which patients with breast cancer are currently eligible for poly(ADP-ribose) polymerase (PARP) inhibition? TT  For this question, I refer to the National Comprehensive Cancer Network […]

Advances in SERDs and Other Novel Endocrine Therapies

H&O  What are the main challenges with endocrine therapy for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer?  KK  The first […]

Novel Endocrine Therapy Agents in ER-Positive, HER2-Negative Breast Cancer

H&O  What types of novel endocrine therapies are being developed for use in estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer? EH  […]

Lessons From Recent Trials of Antibody-Drug Conjugates in Breast Cancer

H&O  Could you describe the activity and safety results of the DESTINY-Breast04 trial?  PT  DESTINY-Breast04 was a landmark phase 3 trial that compared trastuzumab deruxtecan, also […]

New Approaches to Endocrine Therapy in ER-Positive, HER2-Negative Breast Cancer

H&O  What is standard endocrine therapy in estrogen receptor (ER)–positive breast cancer? EH  The selective estrogen receptor modulator (SERM) tamoxifen, which was first introduced in the […]

What Is the Optimal Way to Evaluate Quality of Life in Breast Cancer Trials?

Patricia A. Ganz, MD Professor of Medicine David Geffen School of Medicine at UCLA Los Angeles, California   H&O What are the main quality-of-life issues faced […]